{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:05:33Z","timestamp":1791993933942,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI13\/00047"],"award-info":[{"award-number":["PI13\/00047"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/00298"],"award-info":[{"award-number":["PI15\/00298"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP14\/00133"],"award-info":[{"award-number":["CP14\/00133"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FEDER Funds REDinREN RD12\/0021"],"award-info":[{"award-number":["FEDER Funds REDinREN RD12\/0021"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/02057"],"award-info":[{"award-number":["PI16\/02057"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Programa Intensificacion Actividad Investigadora (ISCIII\/Agencia Lain-Entralgo\/CM)"],"award-info":[{"award-number":["Programa Intensificacion Actividad Investigadora (ISCIII\/Agencia Lain-Entralgo\/CM)"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["MS14\/00133"],"award-info":[{"award-number":["MS14\/00133"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015883","name":"Sociedad Espa\u00f1ola de Nefrologia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015883","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12967-016-1049-8","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T23:46:09Z","timestamp":1476315969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Increased urinary CD80 excretion and podocyturia in Fabry disease"],"prefix":"10.1186","volume":"14","author":[{"given":"H.","family":"Trimarchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Canzonieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Costales-Collaguazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Politei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Paulero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Rengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Forrester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pomeranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Iriarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Muryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D.","family":"Sanchez-Ni\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,13]]},"reference":[{"key":"1049_CR1","doi-asserted-by":"crossref","unstructured":"Desnick RJ, Ioannou Y, Eng CM. \u03b1-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3733\u201374","DOI":"10.1006\/rwgn.2001.0443"},{"key":"1049_CR2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00428-007-0468-6","volume":"451","author":"H Askari","year":"2007","unstructured":"Askari H, Kaneski CR, Semino-Mora C, Desai P, Ang A, Kleiner DE, et al. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch. 2007;451:823\u201334.","journal-title":"Virchows Arch"},{"key":"1049_CR3","doi-asserted-by":"crossref","unstructured":"Merscher S, Fornoni A. Podocyte pathology and nephropathy\u2014sphingolipids in glomerular diseases. Front. Endocrinol. (Lausanne). 2014; 5:127.","DOI":"10.3389\/fendo.2014.00127"},{"key":"1049_CR4","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00467-012-2281-y","volume":"28","author":"A Swiatecka-Urban","year":"2013","unstructured":"Swiatecka-Urban A. Membrane trafficking in podocyte health and disease. Pediatr Nephrol. 2013;28:1723\u201337.","journal-title":"Pediatr Nephrol"},{"key":"1049_CR5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","volume":"1802","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 2010;1802:741\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"1049_CR6","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1161\/01.STR.32.7.1559","volume":"32","author":"G Altarescu","year":"2001","unstructured":"Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke. 2001;32:1559\u201362.","journal-title":"Stroke"},{"key":"1049_CR7","doi-asserted-by":"crossref","first-page":"23594","DOI":"10.1074\/jbc.M300212200","volume":"278","author":"E Lloyd-Evans","year":"2003","unstructured":"Lloyd-Evans E, Pelled D, Riebeling C, Bodennec J, de-Morgan A, Waller H, et al. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J Biol Chem. 2003;278:23594\u20139.","journal-title":"J Biol Chem"},{"key":"1049_CR8","doi-asserted-by":"crossref","first-page":"29496","DOI":"10.1074\/jbc.M302964200","volume":"278","author":"D Pelled","year":"2003","unstructured":"Pelled D, Lloyd-Evans E, Riebeling C, Jeyakumar M, Platt FM, Futerman AH. Inhibition of calcium uptake via the sarco\/endoplasmic reticulum Ca2+\u00a0-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. J Biol Chem. 2003;278:29496\u2013501.","journal-title":"J Biol Chem"},{"key":"1049_CR9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cca.2016.07.016","volume":"461","author":"GB Biancini","year":"2016","unstructured":"Biancini GB, Jacques CE, Hammerschmidt T, de Souza HM, Donida B, Deon M, et al. Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy. Clin Chim Acta. 2016;461:41\u20136.","journal-title":"Clin Chim Acta"},{"key":"1049_CR10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","volume":"1822","author":"GB Biancini","year":"2012","unstructured":"Biancini GB, Vanzin CS, Rodrigues DB, Deon M, Ribas GS, Barschak AG, et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta. 2012;1822:226\u201332.","journal-title":"Biochim Biophys Acta"},{"key":"1049_CR11","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;105:2812\u20137.","journal-title":"Proc Natl Acad Sci USA."},{"key":"1049_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2326409816648169","volume":"4","author":"H Trimarchi","year":"2016","unstructured":"Trimarchi H. The kidney in Fabry disease. More than mere sphyngolipids overload. J Inborn Errors Metab Screen. 2016;4:1\u20135.","journal-title":"J Inborn Errors Metab Screen."},{"key":"1049_CR13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3892\/ijmm.2012.1139","volume":"30","author":"MH Lee","year":"2012","unstructured":"Lee MH, Choi EN, Jeon YJ, Jung S-C. Possible role of transforming growth factor-\u03b21 and vascular endothelial growth factor in Fabry disease nephropathy. Int J Mol Med. 2012;30:1275\u201380.","journal-title":"Int J Mol Med"},{"key":"1049_CR14","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","volume":"24","author":"MD Sanchez-Ni\u00f1o","year":"2015","unstructured":"Sanchez-Ni\u00f1o MD, Carpio D, Sanz AB, Ruiz-Ortega M, Mezzano S, Ortiz A. Lyso-Gb3 activates Notch1 in human podocytes. Hum Mol Genet. 2015;24:5720\u201332.","journal-title":"Hum Mol Genet"},{"key":"1049_CR15","doi-asserted-by":"crossref","first-page":"e63506","DOI":"10.1371\/journal.pone.0063506","volume":"8","author":"MC Liebau","year":"2013","unstructured":"Liebau MC, Braun F, H\u00f6pker K, Weitbrecht C, Bartels V, M\u00fcller R-U, et al. Dysregulated autophagy contributes to podocyte damage in Fabry\u2019s disease. PLoS One. 2013;8:e63506.","journal-title":"PLoS One"},{"key":"1049_CR16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000351516","volume":"3","author":"H Trimarchi","year":"2013","unstructured":"Trimarchi H, Karl A, Ra\u00f1a MS, Forrester M, Pomeranz V, Lombi F, et al. Initially nondiagnosed Fabry\u2019s disease when electron microscopy is lacking: the continuing story of focal and segmental glomerulosclerosis. Case Rep Nephrol Urol. 2013;3:51\u20137.","journal-title":"Case Rep Nephrol Urol."},{"key":"1049_CR17","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","volume":"26","author":"MD Sanchez-Ni\u00f1o","year":"2011","unstructured":"Sanchez-Ni\u00f1o MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant. 2011;26:1797\u2013802.","journal-title":"Nephrol Dial Transplant"},{"key":"1049_CR18","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1681\/ASN.2013050518","volume":"25","author":"P Fiorina","year":"2014","unstructured":"Fiorina P, Vergani A, Bassi R, Niewczas MA, Altintas MM, Pezzolesi MG, et al. Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol. 2014;25:1415\u201329.","journal-title":"J Am Soc Nephrol"},{"key":"1049_CR19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev.iy.11.040193.001203","volume":"11","author":"PS Linsley","year":"1993","unstructured":"Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol. 1993;11:191\u2013212.","journal-title":"Annu Rev Immunol"},{"key":"1049_CR20","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1523-1755.2004.00477.x","volume":"65","author":"Q Wu","year":"2004","unstructured":"Wu Q, Jinde K, Endoh M, Sakai H. Clinical significance of costimulatory molecules CD80\/CD86 expression in IgA nephropathy. Kidney Int. 2004;65:888\u201396.","journal-title":"Kidney Int"},{"key":"1049_CR21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1872214809666150302104542","volume":"9","author":"H Trimarchi","year":"2015","unstructured":"Trimarchi H. Abatacept and glomerular diseases: the open road for the second signal as a new target is settled down. Recent Pat Endocr Metab Immune Drug Discov. 2015;9:2\u201314.","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"1049_CR22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2215\/CJN.01470506","volume":"2","author":"M Hara","year":"2007","unstructured":"Hara M, Yanagihara T, Kihara I. Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Sch\u00f6nlein\u2013Henoch purpura nephritis. Clin J Am Soc Nephrol. 2007;2:231\u20138.","journal-title":"Clin J Am Soc Nephrol."},{"key":"1049_CR23","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1681\/ASN.2005020159","volume":"16","author":"D Yu","year":"2005","unstructured":"Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol. 2005;16:1733\u201341.","journal-title":"J Am Soc Nephrol"},{"key":"1049_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-016-0271-z","author":"H Trimarchi","year":"2016","unstructured":"Trimarchi H, Canzonieri R, Schiel A, Politei J, Stern A, Andrews J, et al. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients. J Nephrol. 2016. doi: 10.1007\/s40620-016-0271-z .","journal-title":"J Nephrol."},{"key":"1049_CR25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5935\/0101-2800.20130043","volume":"35","author":"AR Sabino","year":"2013","unstructured":"Sabino AR, Teixeira VP, Nishida SK, Sass N, Mansur JB, Kirsztajn GM. Detection of podocyturia in patients with lupus nephritis. J Bras Nefrol. 2013;35:252\u20138.","journal-title":"J Bras Nefrol"},{"key":"1049_CR26","doi-asserted-by":"crossref","first-page":"F647","DOI":"10.1152\/ajprenal.00090.2011","volume":"302","author":"M-D Sanchez-Ni\u00f1o","year":"2012","unstructured":"Sanchez-Ni\u00f1o M-D, Bozic M, C\u00f3rdoba-Lan\u00fas E, Valcheva P, Gracia O, Ibarz M, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2012;302:F647\u201357.","journal-title":"Am J Physiol Renal Physiol."},{"key":"1049_CR27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1681\/ASN.2008020194","volume":"20","author":"MD Sanchez-Ni\u00f1o","year":"2009","unstructured":"Sanchez-Ni\u00f1o MD, Sanz AB, Ihalmo P, Lassila M, Holthofer H, Mezzano S, et al. The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol. 2009;20:353\u201362.","journal-title":"J Am Soc Nephrol"},{"key":"1049_CR28","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI20402","volume":"113","author":"J Reiser","year":"2004","unstructured":"Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004;113:1390\u20137.","journal-title":"J Clin Invest."},{"key":"1049_CR29","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00467-016-3387-4","volume":"31","author":"S Ito","year":"2016","unstructured":"Ito S, Ogura M, Kamei K, Matsuoka K, Warnock DG. Significant improvement in Fabry disease podocytopathy after 3\u00a0years of treatment with agalsidase beta. Pediatr Nephrol. 2016;31:1369\u201373.","journal-title":"Pediatr Nephrol"},{"key":"1049_CR30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C T\u00f8ndel","year":"2013","unstructured":"T\u00f8ndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24:137\u201348.","journal-title":"J Am Soc Nephrol"},{"key":"1049_CR31","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795\u2013803.","journal-title":"J Am Soc Nephrol"},{"key":"1049_CR32","first-page":"104","volume":"3","author":"H Trimarchi","year":"2015","unstructured":"Trimarchi H. Primary focal and segmental glomerulosclerosis. Why are there pieces still hidden in this puzzle? Eur Med J Nephrol. 2015;3:104\u201310.","journal-title":"Eur Med J Nephrol."},{"key":"1049_CR33","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","volume":"369","author":"C-C Yu","year":"2013","unstructured":"Yu C-C, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med. 2013;369:2416\u201323.","journal-title":"N Engl J Med"},{"key":"1049_CR34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrneph.2013.276","volume":"10","author":"J Reiser","year":"2014","unstructured":"Reiser J, Alachkar N. Proteinuria: abate or applaud abatacept in proteinuric kidney disease? Nat Rev Nephrol. 2014;10:128\u201330.","journal-title":"Nat Rev Nephrol."},{"key":"1049_CR35","doi-asserted-by":"crossref","first-page":"F335","DOI":"10.1152\/ajprenal.00510.2015","volume":"310","author":"R Novelli","year":"2016","unstructured":"Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS? Am J Physiol Renal Physiol. 2016;310:F335\u201341.","journal-title":"Am J Physiol Renal Physiol."},{"key":"1049_CR36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/path.4692","volume":"239","author":"C Li","year":"2016","unstructured":"Li C, Ge Y, Dworkin L, Peng A, Gong R. The \u03b2 isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy. J Pathol. 2016;239:23\u201335.","journal-title":"J Pathol."},{"key":"1049_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2015.10.033","author":"K-H Chen","year":"2015","unstructured":"Chen K-H, Chien Y, Wang K-L, Leu H-B, Hsiao C-Y, Lai Y-H, et al. Evaluation of proinflammatory prognostic biomarkers for fabry cardiomyopathy with enzyme replacement therapy. Can J Cardiol. 2015. doi: 10.1016\/j.cjca.2015.10.033 .","journal-title":"Can J Cardiol."},{"key":"1049_CR38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0009-8981(98)00169-7","volume":"279","author":"K Utsumi","year":"1999","unstructured":"Utsumi K, Itoh K, Kase R, Shimmoto M, Yamamoto N, Katagiri Y, et al. Urinary excretion of the vitronectin receptor (integrin alpha V beta 3) in patients with Fabry disease. Clin Chim Acta. 1999;279:55\u201368.","journal-title":"Clin Chim Acta"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-016-1049-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T07:13:17Z","timestamp":1589699597000},"score":1,"resource":{"primary":{"URL":"http:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-016-1049-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,13]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1186\/s12967-016-1049-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,13]]},"article-number":"289"}}